Official Title
Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma
Brief Summary

At BMS, we work with physicians/investigators to make investigational products available to patients with life-threatening diseases that have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. When contacted by a treating physician, BMS will consider requests for providing early patient access to Elotuzumab in patients with multiple myeloma who are residents of Belgium, Thailand, Turkey, Argentina, and Colombia.

Detailed Description

Choosing to participate in an early patient access program is an important personal decision. Talk with your doctor and family members or friends about deciding to participate in an early patient access program.

To learn more about early patient access programs, your doctor may contact BMS using the information provided below.

Individual Patients
Multiple Myeloma

Biological: Elotuzumab
Elotuzumab (Emplicitii) is a Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7) directed immunostimulatory antibody approved by the US Food and Drug Administration (FDA) and indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Please contact your physician for more details.
Other Name: Empliciti
Other Name: BMS-901608

Eligibility Criteria

Specific eligibility criteria must be met for access outside of a clinical trial.

These inclusion criteria include:

- The illness must be serious or life threatening

- There are no other viable options (including approved products or active clinical trials)

- There is sufficient evidence that the potential benefit to the patient would likely outweigh the potential risks based on what is known at the time

- Other defined inclusion/exclusion criteria could be applicable.

Eligibility Gender
Eligibility Age
Minimum: 18 Years

Bristol-Myers Squibb, Study Director
Please email:

Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb

Bristol-Myers Squibb
NCT Number
MeSH Terms
Multiple Myeloma
Neoplasms, Plasma Cell